A second health organization in the United Kingdom has officially ended its contract with an Israeli drug manufacturer. This move follows a trend of institutional divestment and contract termination linked to ongoing geopolitical tensions surrounding the conflict in Gaza. Pro-Palestinian activist groups have been actively campaigning for UK institutions to sever ties with Israeli companies, citing concerns over the humanitarian situation in the region.

While the specific identity of the health body and the pharmaceutical firm have not been detailed in initial reports, the development marks a shift in how UK health entities are managing their supply chains in response to public and political pressure. The decision highlights the growing influence of advocacy groups on corporate and public sector procurement policies. Supporters of the move argue that such actions are necessary to hold companies accountable for their association with the Israeli state, while critics often characterize these boycotts as discriminatory or harmful to the stability of medical supply chains. The reports confirm that this is the second such instance of a UK health body taking this step, signaling a potential escalation in the impact of the Boycott, Divestment, and Sanctions (BDS) movement within the British healthcare sector.